XENE insiders were on both sides of the trade this year. Buys came to roughly $1.7 million (two buyers), sales to $22 million (six sellers).
Biggest single buyer: MORTIMER IAN, CEO, with roughly $1.1 million. Notably, at least one C-suite executive was among the buyers.
Big money check: 315 institutions held XENE as of Q2 2026, and more funds bought than sold. Zooming out by quarter: Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | MORTIMER IAN | CEO | Buy | 30,000 | $37.38 | $1.1M | SEC |
| Oct 1, 2026 | Kelly Thomas Patrick | CFO | Buy | 15,000 | $37.32 | $560K | SEC |
| Aug 31, 2026 | KENNEY CHRISTOPHER JOHN | Executive Officer | Sell | 6,368 | $60.17 | $383K | SEC |
| Aug 31, 2026 | KENNEY CHRISTOPHER JOHN | Executive Officer | Sell | 700 | $60.98 | $43K | SEC |
| Aug 13, 2026 | GANNON STEVEN | Director | Sell | 10,000 | $64.06 | $641K | SEC |
| Jun 8, 2026 | PATOU GARY | Director | Sell | 1,322 | $53.14 | $70K | SEC |
| Jun 8, 2026 | Cannon Gillian | Director | Sell | 1,190 | $53.14 | $63K | SEC |
| Mar 13, 2026 | KENNEY CHRISTOPHER JOHN | Executive Officer | Sell | 1,410 | $55.23 | $78K | SEC |
| Mar 13, 2026 | DiFabio Andrea | Executive Officer | Sell | 1,342 | $55.23 | $74K | SEC |
| Mar 13, 2026 | MORTIMER IAN | CEO | Sell | 7,308 | $55.23 | $404K | SEC |
| Mar 11, 2026 | DiFabio Andrea | Executive Officer | Sell | 2,607 | $60.11 | $157K | SEC |
| Mar 11, 2026 | MORTIMER IAN | CEO | Sell | 21,791 | $58.81 | $1.3M | SEC |
| Mar 11, 2026 | MORTIMER IAN | CEO | Sell | 31,694 | $59.88 | $1.9M | SEC |
| Mar 11, 2026 | MORTIMER IAN | CEO | Sell | 10,072 | $60.47 | $609K | SEC |
| Mar 11, 2026 | MORTIMER IAN | CEO | Sell | 2,449 | $61.26 | $150K | SEC |
In the last 12 months Xenon Pharmaceuticals Inc. insiders made open-market purchases worth about $1.7 million and sales worth about $22 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in XENE was filed on 2026-10-01.
315 investment managers reported holding XENE in SEC Form 13F filings for Q2 2026.
No congressional trades in XENE were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).